Expert Recommendations in Relapsed/Refractory Multiple Myeloma

In this on demand webcast, expert faculty discuss best practices in treating patients
with relapsed/refractory multiple myeloma. 

MYSummit Myeloma Conference - Cancelled

Due to the impact of COVID-19, the MYSummit Conference
has been cancelled

Myeloma News

Keep up to date on the latest multiple myeloma news and information.

Featured Content

Myeloma News

Recent Publications

Bullous Amyloidosis Masquerading as Pseudoporphyria

Cutis. 2021 Sep;108(3):E25-E28. doi: 10.12788/cutis.0370. ABSTRACT Amyloidosis is not a singular disease but describes a group of diseases that result from abnormalities in protein folding and metabolism, leading to β-sheet polymers and amyloid fibrils. Cutaneous...

Belantamab mafodotin for the treatment of multiple myeloma

Drugs Today (Barc). 2021 Nov;57(11):653-663. doi: 10.1358/dot.2021.57.11.3319146. ABSTRACT Multiple myeloma is the second most common hematologic malignancy worldwide. Despite the growing number of available therapeutic options and advances in the treatment since the...

Isatuximab for the treatment of multiple myeloma

Drugs Today (Barc). 2021 Nov;57(11):665-675. doi: 10.1358/dot.2021.57.11.3343690. ABSTRACT Isatuximab is an IgG1 monoclonal antibody targeting CD38 that has received regulatory approval in combination regimens for patients with relapsed/refractory multiple myeloma....

Twitter Discussions